A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Trial Profile

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs IRL 790 (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Dec 2017 Status changed from planning to not yet recruiting.
    • 27 Nov 2017 New trial record
    • 17 Aug 2017 According to a Integrative Research Laboratories media release, the company has signed an agreement with The Clinical Trial Company Ltd (TCTC) to conduct this trial in Autumn 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top